FSH levels predict bone loss in premenopausal women treated for breast cancer more than one year after treatment

Laila S. Tabatabai, Joan Bloom, Susan L Stewart, Deborah E. Sellmeyer

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Context: Biomarkers to predict bone loss in premenopausal women after breast cancer treatment have not been examined. Objective: To determine whether baseline FSH predicts subsequent bone loss. Design: Secondary data analysis of the Exercise for Bone Health: Young Breast Cancer Survivors study, in which women were randomized to a 12-month exercise program or monthly health newsletter. Setting: Community dwelling women. Participants:Atotal of 206womenage less than or equal to 55 years at breast cancer diagnosiswho had received adjuvant chemotherapy and were at least 1 year after diagnosis. Intervention: Serum collected at baseline (an average of 302 ± 148 d after completing chemotherapy) was analyzed for FSH. Main Outcome Measure: Change in bone mineral density. Results: In linear regression models, baseline FSH levels predicted bone loss over the ensuing 12 months at the lumbar spine and femoral neck including after adjustment for age, ethnicity, treatment group (exercise vs control), baseline bone density, and high-sensitivity C-reactive protein (P<.001). In multiply adjusted models, the 12-month rate of change in bone density was +0.007% in the lowest tertile of FSH (FSH ± 9 ± 7 IU/L, mean ± SD), 0.96% in the middle tertile (mean FSH ± 41 ± 11 IU/L), and-2.2% in the highest tertile (mean FSH ± 86 ± 19 IU/L), P for trend <.001. Conclusions:Amongpremenopausalwomenwith breast cancer treated with chemotherapy, baseline FSH levels are strongly associated with subsequent bone loss. Further studies are needed to establish the optimal timing of FSH measurement in relation to breast cancer treatment and to investigate potential strategies to prevent bone loss.

Original languageEnglish (US)
Pages (from-to)1257-1262
Number of pages6
JournalJournal of Clinical Endocrinology and Metabolism
Volume101
Issue number4
DOIs
StatePublished - Mar 1 2016

Fingerprint

Bone
Breast Neoplasms
Bone and Bones
Bone Density
Chemotherapy
Exercise
Linear Models
Oncology
Therapeutics
Independent Living
Drug Therapy
Femur Neck
Health
Adjuvant Chemotherapy
C-Reactive Protein
Survivors
Spine
Biomarkers
Outcome Assessment (Health Care)
Linear regression

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Medicine(all)
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

FSH levels predict bone loss in premenopausal women treated for breast cancer more than one year after treatment. / Tabatabai, Laila S.; Bloom, Joan; Stewart, Susan L; Sellmeyer, Deborah E.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 101, No. 4, 01.03.2016, p. 1257-1262.

Research output: Contribution to journalArticle

@article{1536ab9f133e485c94a14dd37edb533f,
title = "FSH levels predict bone loss in premenopausal women treated for breast cancer more than one year after treatment",
abstract = "Context: Biomarkers to predict bone loss in premenopausal women after breast cancer treatment have not been examined. Objective: To determine whether baseline FSH predicts subsequent bone loss. Design: Secondary data analysis of the Exercise for Bone Health: Young Breast Cancer Survivors study, in which women were randomized to a 12-month exercise program or monthly health newsletter. Setting: Community dwelling women. Participants:Atotal of 206womenage less than or equal to 55 years at breast cancer diagnosiswho had received adjuvant chemotherapy and were at least 1 year after diagnosis. Intervention: Serum collected at baseline (an average of 302 ± 148 d after completing chemotherapy) was analyzed for FSH. Main Outcome Measure: Change in bone mineral density. Results: In linear regression models, baseline FSH levels predicted bone loss over the ensuing 12 months at the lumbar spine and femoral neck including after adjustment for age, ethnicity, treatment group (exercise vs control), baseline bone density, and high-sensitivity C-reactive protein (P<.001). In multiply adjusted models, the 12-month rate of change in bone density was +0.007{\%} in the lowest tertile of FSH (FSH ± 9 ± 7 IU/L, mean ± SD), 0.96{\%} in the middle tertile (mean FSH ± 41 ± 11 IU/L), and-2.2{\%} in the highest tertile (mean FSH ± 86 ± 19 IU/L), P for trend <.001. Conclusions:Amongpremenopausalwomenwith breast cancer treated with chemotherapy, baseline FSH levels are strongly associated with subsequent bone loss. Further studies are needed to establish the optimal timing of FSH measurement in relation to breast cancer treatment and to investigate potential strategies to prevent bone loss.",
author = "Tabatabai, {Laila S.} and Joan Bloom and Stewart, {Susan L} and Sellmeyer, {Deborah E.}",
year = "2016",
month = "3",
day = "1",
doi = "10.1210/jc.2015-3149",
language = "English (US)",
volume = "101",
pages = "1257--1262",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "4",

}

TY - JOUR

T1 - FSH levels predict bone loss in premenopausal women treated for breast cancer more than one year after treatment

AU - Tabatabai, Laila S.

AU - Bloom, Joan

AU - Stewart, Susan L

AU - Sellmeyer, Deborah E.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Context: Biomarkers to predict bone loss in premenopausal women after breast cancer treatment have not been examined. Objective: To determine whether baseline FSH predicts subsequent bone loss. Design: Secondary data analysis of the Exercise for Bone Health: Young Breast Cancer Survivors study, in which women were randomized to a 12-month exercise program or monthly health newsletter. Setting: Community dwelling women. Participants:Atotal of 206womenage less than or equal to 55 years at breast cancer diagnosiswho had received adjuvant chemotherapy and were at least 1 year after diagnosis. Intervention: Serum collected at baseline (an average of 302 ± 148 d after completing chemotherapy) was analyzed for FSH. Main Outcome Measure: Change in bone mineral density. Results: In linear regression models, baseline FSH levels predicted bone loss over the ensuing 12 months at the lumbar spine and femoral neck including after adjustment for age, ethnicity, treatment group (exercise vs control), baseline bone density, and high-sensitivity C-reactive protein (P<.001). In multiply adjusted models, the 12-month rate of change in bone density was +0.007% in the lowest tertile of FSH (FSH ± 9 ± 7 IU/L, mean ± SD), 0.96% in the middle tertile (mean FSH ± 41 ± 11 IU/L), and-2.2% in the highest tertile (mean FSH ± 86 ± 19 IU/L), P for trend <.001. Conclusions:Amongpremenopausalwomenwith breast cancer treated with chemotherapy, baseline FSH levels are strongly associated with subsequent bone loss. Further studies are needed to establish the optimal timing of FSH measurement in relation to breast cancer treatment and to investigate potential strategies to prevent bone loss.

AB - Context: Biomarkers to predict bone loss in premenopausal women after breast cancer treatment have not been examined. Objective: To determine whether baseline FSH predicts subsequent bone loss. Design: Secondary data analysis of the Exercise for Bone Health: Young Breast Cancer Survivors study, in which women were randomized to a 12-month exercise program or monthly health newsletter. Setting: Community dwelling women. Participants:Atotal of 206womenage less than or equal to 55 years at breast cancer diagnosiswho had received adjuvant chemotherapy and were at least 1 year after diagnosis. Intervention: Serum collected at baseline (an average of 302 ± 148 d after completing chemotherapy) was analyzed for FSH. Main Outcome Measure: Change in bone mineral density. Results: In linear regression models, baseline FSH levels predicted bone loss over the ensuing 12 months at the lumbar spine and femoral neck including after adjustment for age, ethnicity, treatment group (exercise vs control), baseline bone density, and high-sensitivity C-reactive protein (P<.001). In multiply adjusted models, the 12-month rate of change in bone density was +0.007% in the lowest tertile of FSH (FSH ± 9 ± 7 IU/L, mean ± SD), 0.96% in the middle tertile (mean FSH ± 41 ± 11 IU/L), and-2.2% in the highest tertile (mean FSH ± 86 ± 19 IU/L), P for trend <.001. Conclusions:Amongpremenopausalwomenwith breast cancer treated with chemotherapy, baseline FSH levels are strongly associated with subsequent bone loss. Further studies are needed to establish the optimal timing of FSH measurement in relation to breast cancer treatment and to investigate potential strategies to prevent bone loss.

UR - http://www.scopus.com/inward/record.url?scp=84960843836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960843836&partnerID=8YFLogxK

U2 - 10.1210/jc.2015-3149

DO - 10.1210/jc.2015-3149

M3 - Article

VL - 101

SP - 1257

EP - 1262

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 4

ER -